Analyst firms · Citigroup · SMMT
Citigroup SMMT price target and rating history
Summit Therapeutics Inc. (SMMT) · Health Care
Citigroup rates Summit Therapeutics Inc. (SMMT) Buy with a $35 price target, as of its latest action on Mar 26, 2025. It has published 3 rating actions on SMMT since May 2024, including 1 upgrade and 1 downgrade. Across 5 firms with a SMMT price target in the last 12 months, the median target is $18.
- Current rating
- Buy
- Price target
- $35
- Median target, all firms
- $18
- Actions on SMMT
- 3
Citigroup price target on SMMT
Every Citigroup rating on SMMT
- Mar 26, 2025
- Sep 27, 2024
- May 7, 2024
How other firms rate SMMT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Jefferies | Buy | $25 | Sep 9, 2026 |
| Bernstein | Mkt Perform | $11.90 | Aug 25, 2026 |
| Leerink Partners | Market Perform | $13 | Aug 12, 2026 |
| H.C. Wainwright | Neutral | May 22, 2026 | |
| Stifel | Buy | $45 | Apr 8, 2026 |
| Barclays | Equal Weight | $18 | Dec 17, 2025 |
| Wolfe Research | Peer Perform | Nov 18, 2025 |
Questions about Citigroup and SMMT
- What is Citigroup's price target for SMMT?
- Citigroup's latest stated price target for Summit Therapeutics Inc. (SMMT) is $35, from its action on Mar 26, 2025.
- What is Citigroup's rating on SMMT?
- Citigroup rates SMMT Buy, a bullish rating, as of Mar 26, 2025.
- When did Citigroup last change its view on SMMT?
- On Mar 26, 2025, Citigroup upgrades to Buy from Neutral, price target $23 to $35.
- How does Citigroup's SMMT target compare with other analysts?
- Across 5 firms with a SMMT price target in the last 12 months, the median target is $18.
More SMMT rating histories
All Citigroup ratingsSMMT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.